REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot1363Original ArticleCerebrolysin® is currently enjoying a new lease on lifeProzherinaJulianoemail@neicon.ruRemedium1512201813S15716218032022Copyright © 2018,2018The high prevalence of neurological diseases, primarily ischemic stroke and cognitive impairments, dictate the need for a rational choice of the most effective drugs. It was previously thought that vasoactive drugs are of the greatest importance for the recovery of brain functions, now the emphasis is shifted towards neuroprotective and neurotrophic agents. One such an example is Cerebrolysin® (EVER Neuro Pharma, Austria) resulting from extracting the peptide fraction of the young pigs brain [1]. This brand is well known to a wide range of Russian clinicians, primarily neurologists and psychiatrists [2]. However, even those health professionals who are already familiar with the drug should look at it again: Cerebrolysin® is currently enjoying a new lease on life.1.Gromova OA, Torshin IYu, Gogoleva IV. Mechanisms of neurotrophic and neuroprotective action of Cerebrolysin in cerebral ischemia. Zhurnal Nevrologii I Psihiatrii, 2014, 3(Issue 2): 43-50.2.The official website for Cerebrolysin.3.Clinical guidelines. Diagnosis and treatment of organic mental disorders. Agreed by Kekelidze ZI, Neznanov NG. Moscow. 2014.4.Lazareva AV. Affective disorders in organic cerebral diseases in elderly. Extended abstract of PhD in medicine Dissertation. Moscow, 2017.5.Vishnevskaya M., et al. Administration of Cerebrolysin in neuro-protection and neuroregeneration (literature review). Mezhdunarodny Nevrologicheski Zhurnal, 2015, 8(78): 55-63.6.Afanasyev VV, Rumyantseva SA. Cerebrolysin. Features of clinical use. Atmosfera. Nervnye Bolezni, 2010, 3: 13-16.7.Gordeeva IE, Ansarov KhSh, Sokolova VYu. Efficacy of Cerebrolysin in chronic cerebral ischemia. Effektivnaya Farmakoterapiya, 2018, 1: 6-8.8.Parfenov VA, Kabaeva AR. Management of patients with Alzheimer's disease. Medical Council, 2018, 1: 6-12.9.Patient Information Leaflet for Cerebrolysin®.10.Chukanova EI. Cerebrolysin helped in the treatment of chronic cerebral ischemia and stroke prevention for over 60 years. A new strategy is health of the nation, 2017, 1(38): 34.11.Gauthier S, Proano JV, Jia J, et al. Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials. Dement Geriatr Cogn Disord, 2015, 39: 340-55.12.Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke, 2012, 43(3): 630-6. doi: 10.1161 / STROKEAHA.111.628537.13.The role of Cerebrolysin in rehabilitation after ischemic stroke. The 9th International Congress Neurorehabilitation - 2017. Effective pharmacotherapy, 2017, 33.14.Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, Rahlfs VW, Doppler E, Meier D, Moessler H, Guekht A. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke, 2016, 47(1): 151-9. doi: 10.1161 / STROKEAHA.115.009416.15.Grigorova IG, et al. Cerebrolysin in the treatment of young patients with craniocerebral and craniofacial trauma. Mezhdunarodny Nevrologicheski Zhurnal, 2006, 6(10).